CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗后神经毒性相关窦性心动过缓
英文原题：Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.
查看英文原题
Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法的出现改变了复发/难治性侵袭性B细胞淋巴瘤的治疗格局。细胞因子释放综合征和免疫效应细胞相关神经毒性综合征（ICANS）是与此疗法相关的典型不良事件。在此背景下，也有心血管毒性的报道。然而，关于CAR-T 细胞疗法后发生窦性心动过缓的数据很少。在此，我们详细描述了4例接受CAR-T 细胞治疗并在ICANS背景下出现短暂且可逆性窦性心动过缓的侵袭性B细胞恶性肿瘤患者的临床过程。我们还讨论了这一潜在新不良事件病理生理学背后的若干假说。
展开英文摘要原文
The advent of chimeric antigen receptor (CAR) T-cell therapy has changed the therapeutic landscape of relapsed/refractory aggressive B-cell lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS) are the typical adverse events associated with this therapy. Cardiovascular toxicities have also been reported in this setting.
However, there is scarce data regarding the development of sinus bradycardia after CAR T-cell therapy.
Here, we detail the clinical course of 4 patients with aggressive B-cell malignancies who received CAR T-cells and developed transient and reversible sinus bradycardia in the context of ICANS.
We also discuss several hypotheses behind the pathophysiology of this potential new adverse event.
论文信息
- 作者
- Catalá E、Iacoboni G、Vidal-Jordana Á、Oristrell G、Carpio C、Vilaseca A、Cabirta A、Bosch F
- 单位
- Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.Spain
- 文献类型
- 读者来信
- 期刊
- Hematological oncology2022 Aug
- 原文标识
- PubMed 35139240 · DOI 10.1002/hon.2976